Synlogic (SYBX)
OTHER OTC:SYBX
Want to see SYBX full AI Analyst Report?
Top Page
Synlogic
(OTC:SYBX)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.67
▼(-44.92% Downside)
Action:ReiteratedDate:03/13/26
The score is driven primarily by weak financial performance (minimal/unstable revenue, persistent losses, and ongoing cash burn) alongside a major negative corporate event (Nasdaq delisting to OTC). Technicals reinforce downside trend conditions, while valuation metrics offer limited support due to negative earnings and no dividend.
Positive Factors
Platform-based engineered microbial medicines
A platform approach to program microbes for multiple metabolic and immunology indications provides structural optionality: successful science can be applied across programs, enabling pipeline diversification and potential licensing or partnership value that persists beyond short-term trials.
Negative Factors
Shrinking equity base from cumulative losses
A severe decline in equity reflects cumulative operating losses and weak capital retention, reducing the firm’s buffer against adverse outcomes. This erosion constrains financing options, increases dilution risk, and limits strategic flexibility over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform-based engineered microbial medicines
A platform approach to program microbes for multiple metabolic and immunology indications provides structural optionality: successful science can be applied across programs, enabling pipeline diversification and potential licensing or partnership value that persists beyond short-term trials.
Read all positive factors
Synlogic (SYBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.43M
Dividend YieldN/A
Average Volume (3M)41.08K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth-100.00%
EPS Growth97.01%
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,698,919
10 Day Avg. Volume24,108
30 Day Avg. Volume41,078
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.16
Enterprise Value/Market Cap-1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda2.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Synlogic Business Overview & Revenue Model
Company Description
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SY...
How the Company Makes Money
null...
Synlogic Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 8.00K | 3.37M | 1.18M | 1.75M |
| Gross Profit | 0.00 | 8.00K | 3.37M | 1.18M | 1.75M |
| EBITDA | -3.53M | -22.06M | -55.31M | -63.63M | -58.12M |
| Net Income | -1.00M | -23.36M | -57.28M | -66.15M | -60.56M |
Balance Sheet | |||||
| Total Assets | 15.45M | 19.83M | 75.55M | 110.86M | 174.74M |
| Cash, Cash Equivalents and Short-Term Investments | 14.67M | 18.86M | 47.75M | 77.63M | 128.59M |
| Total Debt | 0.00 | 0.00 | 17.27M | 20.30M | 20.59M |
| Total Liabilities | 3.58M | 7.08M | 32.90M | 28.25M | 27.47M |
| Stockholders Equity | 11.86M | 12.75M | 42.66M | 82.61M | 147.27M |
Cash Flow | |||||
| Free Cash Flow | -4.36M | -31.67M | -51.83M | -57.62M | -52.88M |
| Operating Cash Flow | -4.36M | -31.66M | -51.61M | -56.89M | -52.20M |
| Investing Cash Flow | 167.00K | 25.34M | 38.77M | 58.35M | -53.25M |
| Financing Cash Flow | 0.00 | 172.00K | 20.94M | -2.04M | 89.38M |
Synlogic Technical Analysis
Negative
1.22
Price Trends
0.63
Positive
0.85
Negative
1.21
Negative
Market Momentum
>-0.01
Negative
48.42
Neutral
53.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYBX, the sentiment is Negative. The current price of 1.22 is above the 20-day moving average (MA) of 0.64, above the 50-day MA of 0.63, and above the 200-day MA of 1.21, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.42 is Neutral, neither overbought nor oversold. The STOCH value of 53.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SYBX.
Synlogic Risk Analysis
Synlogic disclosed 33 risk factors in its most recent earnings report. Synlogic reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Synlogic Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $21.67M | -1.15 | -112.05% | ― | ― | 99.89% | |
47 Neutral | $5.81M | >-0.01 | -389.34% | ― | ― | 98.91% | |
47 Neutral | $15.22M | -4.09 | -290.37% | ― | 814.07% | 89.12% | |
45 Neutral | $28.18M | -0.97 | -84.39% | ― | -83.00% | 20.34% | |
44 Neutral | $64.44M | -1.05 | -515.34% | ― | ― | 73.34% | |
40 Underperform | $7.43M | -13.72 | -27.54% | ― | -100.00% | 97.01% |
* Healthcare Sector Average
SYBX
Synlogic
0.64
-0.50
-43.86%
LSTA
Lisata Therapeutics
3.20
0.83
35.02%
APVO
Aptevo Therapeutics
4.91
-185.89
-97.43%
ICU
SeaStar Medical Holding
3.92
-8.98
-69.61%
CING
Cingulate Inc
4.68
0.47
11.16%
ALLR
Allarity Therapeutics
1.37
0.17
14.17%
Synlogic Corporate Events
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Synlogic to Delist from Nasdaq and Move to OTC
Negative
Jan 20, 2026
On November 21, 2025, Synlogic received a notice from Nasdaq’s Listing Qualifications Department stating that, based on its review of the company’s public disclosures, it believed Synlogic had become a public shell and that continued l...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.